Dr Schöffski presents, at a press conference at ASCO 2015, findings from a randomised phase III trial point to a promising new therapy for patients with advanced intermediate or high grade liposarcoma or leiomyosarcoma whose disease worsened after two or more lines of initial therapies.
Read the news article for more.